Dario demonstrates 12 months of sustained healthy behavior change for members taking a glp-1

New research confirms behavior change driven by dario digital platform is sustainable for 12 month period and supports clinical results for members taking a glp-1 additional research demonstrates 31% of dario members with type 2 diabetes achieve results reflecting diabetes remission new york , june 25, 2024 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, announced today two new studies presented this past weekend at the 84th annual american diabetes association (ada) scientific sessions in orlando. the first study provides an analysis of member data for those tracking a glp-1 medication in dario's cardiometabolic solution.
DRIO Ratings Summary
DRIO Quant Ranking